Burning Rock's STELLA Shows 65.9% Sensitivity, 97.2% Specificity in Breast Lesion Study

Bitget2026/10/27 02:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Burning Rock Biotech presented STELLA breast lesion clinical validation results at the ESMO Congress on October 27, 2026.
The 516-patient PERCEIVE-BREAST study showed potential for STELLA to help distinguish malignant from benign breast lesions alongside conventional imaging.
Detection improved with disease stage; negative results alone cannot rule out malignancy, requiring follow-up imaging and pathological examination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Burning Rock's STELLA Shows 65.9% Sensitivity, 97.2% Specificity in Breast Lesion Study

You may also like

Crypto prices